Skip to main content
. 2019 Aug 15;11(8):5076–5085.

Figure 2.

Figure 2

6KApoEp attenuates LPS-induced p44/42 MAPK phosphorylation. BV2 microglia were treated with LPS at 100 ng/ml in the absence or presence of 6KApoEp at 10 µM for 0, 15, 30 or 60 min. Total (p38 and p44/42) and phosphorylated p38 and p44/42 MAPK (P-p38 and P-p44/42) in cell lysates was determined by WB, utilizing anti-total p38 (Cell Signaling, #9212), anti-total p44/42 (#4695), anti-phospho p38 (#4511) and anti-phospho p44/42 antibodies (#4370) (A-D). In addition, BV2 cells were pretreated with the p38 MAPK inhibitor SB203580 at 20 µM, the p44/42 MAPK inhibitor PD98059 at 50µM or 6KApoEp at 10µM for 60 min followed by treatment with LPS at 100 ng/ml for 60 min (E-H). Representative blots are shown for each condition and band density ratio of phospho-p38 to total p38 and phospho-p44/42 to total p44/42 MAPK determined by densitometry analysis are shown below each blot. Full non-adjusted images of WB shown in Figure S1. PD98059 and 6KApoEp reduced LPS-induced p44/42 MAPK phosphorylation while enhancing p38 MAPK phosphorylation. In contrast, SB203580 reduced LPS-induced p38 MAPK phosphorylation while enhancing p44/42 MAPK phosphorylation. Total p38 and p44/42 MAPK were similar across conditions. Results expressed as means ± S.E.M of three experiments. Asterisk indicates P < 0.05 compared with LPS alone.